https://www.prnewswire.com/news-releases/gannex-and-galmed-expand-development-programs-for-nash-through-research-collaboration-of-aramchol-and-asc41-thr-beta-agonist-301126220.html
/PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672) and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announces...
gannexexpanddevelopmentprogramsnash